RLY-2608

· Relay Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for RLY-2608, covering 2025-09-22 to 2026-04-02. Get the full timeline:

Most recent: Clinical Trial Update: Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer [Phase 3]

See pricing